Search

Search Constraints

You searched for: Author/Creator Mourey, Loïc

Search Results

1. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Issue 10336 (30th April 2022)

4. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Issue 7 (July 2015)

5. Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study. (January 2015)

7. Impact of a comprehensive geriatric assessment on decision‐making in older patients with hematological malignancies. (14th February 2021)

8. Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. (5th March 2021)

9. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. (February 2019)

10. Spreading geriatric oncology culture through professional caregivers: Results of a French massive open online course (MOOC). Issue 1 (January 2022)